Is immunotherapy safe and effective in patients with VEXAS syndrome?
The use of immune checkpoint inhibitors in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is unknown. Concerns are particularly about their safety, due to their potential capacity to exacerbate inflammatory symptoms. Further, there is a lack of data about their role in con...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-07-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/7/e012410.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850070286719778816 |
|---|---|
| author | Chiara Marvisi Francesco Muratore Carlo Salvarani Davide Nicoli Enrico Farnetti Lucia Spaggiari Vincenza Ylenia Cusenza Orsola Bonanno Maria Banzi Caterina Longo |
| author_facet | Chiara Marvisi Francesco Muratore Carlo Salvarani Davide Nicoli Enrico Farnetti Lucia Spaggiari Vincenza Ylenia Cusenza Orsola Bonanno Maria Banzi Caterina Longo |
| author_sort | Chiara Marvisi |
| collection | DOAJ |
| description | The use of immune checkpoint inhibitors in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is unknown. Concerns are particularly about their safety, due to their potential capacity to exacerbate inflammatory symptoms. Further, there is a lack of data about their role in controlling the UBA1 clones. In this clinical case, we report a successful use of cemiplimab in a patient with VEXAS syndrome and a concomitant diagnosis of metastatic squamous cell carcinoma. |
| format | Article |
| id | doaj-art-b82e2cb72f4b4eb991351d48fdf2f0eb |
| institution | DOAJ |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-b82e2cb72f4b4eb991351d48fdf2f0eb2025-08-20T02:47:35ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-07-0113710.1136/jitc-2025-012410Is immunotherapy safe and effective in patients with VEXAS syndrome?Chiara Marvisi0Francesco Muratore1Carlo Salvarani2Davide Nicoli3Enrico Farnetti4Lucia Spaggiari5Vincenza Ylenia Cusenza6Orsola Bonanno7Maria Banzi8Caterina Longo9Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, ItalyAzienda USL - IRCCS di Reggio Emilia, Reggio Emilia, ItalyAzienda USL - IRCCS di Reggio Emilia, Reggio Emilia, ItalyAzienda USL - IRCCS di Reggio Emilia, Reggio Emilia, ItalyAzienda USL - IRCCS di Reggio Emilia, Reggio Emilia, ItalyAzienda USL - IRCCS di Reggio Emilia, Reggio Emilia, ItalyAzienda USL - IRCCS di Reggio Emilia, Reggio Emilia, ItalyAzienda USL - IRCCS di Reggio Emilia, Reggio Emilia, ItalyAzienda USL - IRCCS di Reggio Emilia, Reggio Emilia, ItalyAzienda USL - IRCCS di Reggio Emilia, Reggio Emilia, ItalyThe use of immune checkpoint inhibitors in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is unknown. Concerns are particularly about their safety, due to their potential capacity to exacerbate inflammatory symptoms. Further, there is a lack of data about their role in controlling the UBA1 clones. In this clinical case, we report a successful use of cemiplimab in a patient with VEXAS syndrome and a concomitant diagnosis of metastatic squamous cell carcinoma.https://jitc.bmj.com/content/13/7/e012410.full |
| spellingShingle | Chiara Marvisi Francesco Muratore Carlo Salvarani Davide Nicoli Enrico Farnetti Lucia Spaggiari Vincenza Ylenia Cusenza Orsola Bonanno Maria Banzi Caterina Longo Is immunotherapy safe and effective in patients with VEXAS syndrome? Journal for ImmunoTherapy of Cancer |
| title | Is immunotherapy safe and effective in patients with VEXAS syndrome? |
| title_full | Is immunotherapy safe and effective in patients with VEXAS syndrome? |
| title_fullStr | Is immunotherapy safe and effective in patients with VEXAS syndrome? |
| title_full_unstemmed | Is immunotherapy safe and effective in patients with VEXAS syndrome? |
| title_short | Is immunotherapy safe and effective in patients with VEXAS syndrome? |
| title_sort | is immunotherapy safe and effective in patients with vexas syndrome |
| url | https://jitc.bmj.com/content/13/7/e012410.full |
| work_keys_str_mv | AT chiaramarvisi isimmunotherapysafeandeffectiveinpatientswithvexassyndrome AT francescomuratore isimmunotherapysafeandeffectiveinpatientswithvexassyndrome AT carlosalvarani isimmunotherapysafeandeffectiveinpatientswithvexassyndrome AT davidenicoli isimmunotherapysafeandeffectiveinpatientswithvexassyndrome AT enricofarnetti isimmunotherapysafeandeffectiveinpatientswithvexassyndrome AT luciaspaggiari isimmunotherapysafeandeffectiveinpatientswithvexassyndrome AT vincenzayleniacusenza isimmunotherapysafeandeffectiveinpatientswithvexassyndrome AT orsolabonanno isimmunotherapysafeandeffectiveinpatientswithvexassyndrome AT mariabanzi isimmunotherapysafeandeffectiveinpatientswithvexassyndrome AT caterinalongo isimmunotherapysafeandeffectiveinpatientswithvexassyndrome |